FFAR3 and colitis: This knowledge about the role of SCFAs and GPR receptors in the therapeutic effects of XYKJP is crucial for understanding how XYKJP relieves the symptoms of colitis by modulating intestinal flora dysbiosis, improving beneficial bacterial abundance, increasing the concentration of SCFAs, and activating GPR41 /43 receptors.